The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.0M data for 1.3M Compounds and 9.6K Targets. Of those, 1.5M data for 695K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

13 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Recent advances in DDR (DNA damage response) inhibitors for cancer therapy.EBI
Hubei Polytechnic University
BAY-8400: A Novel Potent and Selective DNA-PK Inhibitor which Shows Synergistic Efficacy in Combination with Targeted Alpha Therapies.EBI
Bayer
Synthetic Lethality through the Lens of Medicinal Chemistry.EBI
Istituto Italiano Di Tecnologia
ATR Inhibitors as Potential Treatment for Cancers.EBI
Therachem Research Medilab
Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amineBDB
Kronos Bio
Cycloalkyl-diamines for the treatment of inflammationBDB
Medisynergics
Pyrazole derivatives as MALT1 inhibitorsBDB
Janssen Pharmaceutica
Bicyclic heterocyclic compoundBDB
Mitsubishi Tanabe Pharma
Substituted pyrazoloazepin-8-ones and their use as phosphodiesterase inhibitorsBDB
Leo Pharma
Substituted [5,6]cyclic-4(3H)-pyrimidinones as anticancer agentsBDB
Zenji Research Laboratories
Compounds and their use for reducing uric acid levelsBDB
Acquist
Sulfur-containing compounds targeting vesicular acetylcholine transporterBDB
Washington University
3-amino-pyridines as GPBAR1 agonistsBDB
Hoffmann-La Roche